<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02325063</url>
  </required_header>
  <id_info>
    <org_study_id>PHRC-I/2013/MV-01</org_study_id>
    <secondary_id>2014-001300-22</secondary_id>
    <nct_id>NCT02325063</nct_id>
  </id_info>
  <brief_title>Evaluation of Three Types of Injection for the Treatment of Lateral Epicondylalgia</brief_title>
  <acronym>LET</acronym>
  <official_title>Leukocyte and Platelet Rich Plasma Versus Type A Botulinum Toxin Versus Glucocorticoids for the Treatment of Lateral Epicondylalgia: a Randomized, Multicenter, Double-blind, Therapeutic Trial With Three Parallel Arms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nīmes</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nīmes</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to compare the evolution of pain profiles among&#xD;
      patients suffering from lateral epicondyalgia (tennis elbow) following three types of&#xD;
      treatment: PRP-L injection versus type A botulinum toxin injection versus corticoid&#xD;
      injection.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The secondary objectives are to compare the following among the three groups:&#xD;
&#xD;
      A- The global efficacy of each treatment defined by a minimum reduction of 25% in average&#xD;
      pain over the last 24 hours between 0 and 6 months.&#xD;
&#xD;
      B- The evolution of average pain over the last 24 hours between 0 and each different time&#xD;
      frame (3 weeks, 6 weeks, 3 months and 6 months).&#xD;
&#xD;
      C- The evolution of maximum pain scores using nocturnal post-effort (Jamar grip test) visual&#xD;
      analog scales (VAS) between day 0, 3 weeks, 6 weeks, 3 months and 6 months.&#xD;
&#xD;
      D- The perception of change on the Patient's Global Impression of Change score (PGIC) at 3&#xD;
      and 6 months E- The evolution of PRTEE scores at 0, 3 and 6 months F- Adverse events at 3&#xD;
      weeks, 6 weeks, 3 months and 6 months. G - Quality of life and utility via the SF-12 at 3 and&#xD;
      6 months. H- The consumption of analgesics.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Stop production PRB kit&#xD;
  </why_stopped>
  <start_date type="Actual">December 17, 2015</start_date>
  <completion_date type="Actual">May 2, 2017</completion_date>
  <primary_completion_date type="Actual">May 2, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Visual analog scale (VAS) for pain over the last 24 hours</measure>
    <time_frame>6 months versus Baseline (day 0)</time_frame>
    <description>score varying from 0 to 10</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual analog scale for pain over the last 24 hours</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <description>score varying from 0 to 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analog scale for pain over the last 24 hours</measure>
    <time_frame>3 weeks</time_frame>
    <description>score varying from 0 to 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analog scale for pain over the last 24 hours</measure>
    <time_frame>6 weeks</time_frame>
    <description>score varying from 0 to 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Visual analog scale for pain over the last 24 hours</measure>
    <time_frame>3 months</time_frame>
    <description>score varying from 0 to 10</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Global efficacy</measure>
    <time_frame>6 months</time_frame>
    <description>Defined as the proportion of patients for whom a decrease in visual analog scales for pain over the last 24 hours of at least 25% has been observed over the past 6 months.</description>
  </other_outcome>
  <other_outcome>
    <measure>VAS for pain after a Jamar grip test</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <description>score varying from 0 to 10</description>
  </other_outcome>
  <other_outcome>
    <measure>VAS for pain after a Jamar grip test</measure>
    <time_frame>3 months</time_frame>
    <description>score varying from 0 to 10</description>
  </other_outcome>
  <other_outcome>
    <measure>VAS for pain after a Jamar grip test</measure>
    <time_frame>6 months</time_frame>
    <description>score varying from 0 to 10</description>
  </other_outcome>
  <other_outcome>
    <measure>PRTEE Score</measure>
    <time_frame>Baseline (day 0)</time_frame>
    <description>The Patient-Rated Tennis Elbow Evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>PRTEE Score</measure>
    <time_frame>3 months</time_frame>
    <description>The Patient-Rated Tennis Elbow Evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>PRTEE Score</measure>
    <time_frame>6 months</time_frame>
    <description>The Patient-Rated Tennis Elbow Evaluation</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Global Impression of Change</measure>
    <time_frame>3 months</time_frame>
    <description>score varying from 1 to 7</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Global Impression of Change</measure>
    <time_frame>6 months</time_frame>
    <description>score varying from 1 to 7</description>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with adverse effects</measure>
    <time_frame>Baseline (day 0)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with adverse effects</measure>
    <time_frame>3 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with adverse effects</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with adverse effects</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Number of patients with adverse effects</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The SF 12 questionnaire</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The SF 12 questionnaire</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The consumption of analgesics.</measure>
    <time_frame>Baseline (day 0)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The consumption of analgesics.</measure>
    <time_frame>3 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The consumption of analgesics.</measure>
    <time_frame>6 weeks</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The consumption of analgesics.</measure>
    <time_frame>3 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>The consumption of analgesics.</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Epicondylitis, Lateral Humeral</condition>
  <condition>Tennis Elbow</condition>
  <arm_group>
    <arm_group_label>PRP-L Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized to this group will be treated with an injection of Leukocyte and Platelet Rich Plasma (PRP-L).&#xD;
Intervention: PRP-L Injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Botox Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to this group will be treated with an injection of Type A Botulinum Toxin (Xeomin®, MERZ).&#xD;
Intervention: Botox injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Corticoid Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients randomized to this group will be treated with an injection of Corticoids.&#xD;
Intervention: Corticoid injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRP-L Injection</intervention_name>
    <description>Patients will be treated with an injection of leukocyte and platelet rich plasma.</description>
    <arm_group_label>PRP-L Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botox injection</intervention_name>
    <description>Patients will be treated with an injection of Type A Botulinum toxin.</description>
    <arm_group_label>Botox Group</arm_group_label>
    <other_name>Type A Botulinum toxin injection</other_name>
    <other_name>Xeomin®, MERZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Corticoid injection</intervention_name>
    <description>Patients will be treated with an injection of Corticoids.</description>
    <arm_group_label>Corticoid Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General inclusion criteria:&#xD;
&#xD;
          -  The patient must have given free and informed consent and signed the consent&#xD;
&#xD;
          -  The patient must be affiliated or beneficiary to a health insurance plan&#xD;
&#xD;
          -  The patient is available for 6 months of follow-up&#xD;
&#xD;
          -  Woman of childbearing age using contraception&#xD;
&#xD;
        Inclusion criteria for the target population: the patient has a side epicondylalgia&#xD;
        objectified by:&#xD;
&#xD;
          -  Clinical criteria: symptoms lasting for more than 6 weeks and less than 12 months. The&#xD;
             list of symptoms to be present are: pain on palpation of the lateral epicondyle, pain&#xD;
             in the lateral epicondyle during blocked contraction&#xD;
&#xD;
          -  Therapeutic: less than two injections of corticosteroids performed, and the last such&#xD;
             injection was performed at least 3 months before inclusion&#xD;
&#xD;
        General non-inclusion criteria:&#xD;
&#xD;
          -  The patient is participating in another study&#xD;
&#xD;
          -  The patient is exclusion period determined by a previous study&#xD;
&#xD;
          -  The patient is under judicial protection&#xD;
&#xD;
          -  The patient is under guardianship or curatorship&#xD;
&#xD;
          -  The patient refuses to sign the consent&#xD;
&#xD;
          -  Woman of childbearing age not using contraception&#xD;
&#xD;
          -  Impossible to correction inform the patient about the study&#xD;
&#xD;
        Non-inclusion criteria for investigational and auxiliary medicinal products:&#xD;
&#xD;
          -  The patient has at least one of the contra-indications listed in the SPC for Xeomin&#xD;
             and ALTIM:&#xD;
&#xD;
          -  Hypersensitivity to Botulinum neurotoxin type A or Cortivazol&#xD;
&#xD;
          -  Hypersensitivity to any of the excipients used in the composition of XEOMIN (Human&#xD;
             albumin, sucrose) and / or ALTIM (Benzyl alcohol, carmellose sodium, sodium chloride,&#xD;
             cetylpyridinium chloride, polysorbate 80)&#xD;
&#xD;
          -  Generalized disorders of muscle activity (eg myasthenia gravis, Lambert-Eaton&#xD;
             syndrome).&#xD;
&#xD;
          -  Severe coagulation disorders, anticoagulation in progress (ticlopidine, clopidogrel,&#xD;
             other antiplatelet or antithrombotic agents)&#xD;
&#xD;
          -  Presence of a local or general infection, suspected infection, infection at the&#xD;
             proposed injection site.&#xD;
&#xD;
        Non-inclusion criteria for the medical device used for the PRP samples (SmartPReP2 sampling&#xD;
        system):&#xD;
&#xD;
          -  Clinical or laboratory evidence for sepsis&#xD;
&#xD;
          -  Taking aspirin or other drugs altering platelet function in the previous 3 days&#xD;
&#xD;
          -  Patient with the platelet dysfunction disorders&#xD;
&#xD;
        Non-inclusion criteria for interfering diseases or conditions:&#xD;
&#xD;
          -  The patient is pregnant, parturient or she is breastfeeding&#xD;
&#xD;
          -  The patient has an allergy to botulinum toxin type A and / or glucocorticoids&#xD;
&#xD;
          -  The patient has medial epicondylalgia&#xD;
&#xD;
          -  The patient has a history of elbow surgery&#xD;
&#xD;
          -  The patient has any of the following conditions: immunodeficiency, rheumatic disease,&#xD;
             hepatitis, diabetes, another disease of the ipsilateral limb, neurological disorder&#xD;
             (radiculopathy, compression of the radial nerve), any myopathy (all etiologies)&#xD;
&#xD;
          -  The patient received treatment with corticosteroids in the last 3 months&#xD;
&#xD;
          -  The patient is being treated with long-term anti-platelet medication&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthieu Vaucher, MD</last_name>
    <role>Study Director</role>
    <affiliation>Centre Hospitalier Universitaire de Nîmes</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>CHRU de Montpellier - Hôpital Lapeyronie</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHRU de Nîmes - Hôpital Universitaire Carémeau</name>
      <address>
        <city>Nîmes Cedex 09</city>
        <zip>30029</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2017</verification_date>
  <study_first_submitted>December 19, 2014</study_first_submitted>
  <study_first_submitted_qc>December 23, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2014</study_first_posted>
  <last_update_submitted>June 16, 2017</last_update_submitted>
  <last_update_submitted_qc>June 16, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tennis Elbow</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Botulinum Toxins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

